Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.
BACKGROUND: In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer. However, uncertainty remains on the exact dose-risk and duration-risk relationships. METHODS: We identified studies by searching several English and Chinese electronic databases and reviewi...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3581483?pdf=render |
id |
doaj-a9e68da3536a4a61af053e1be4bf2529 |
---|---|
record_format |
Article |
spelling |
doaj-a9e68da3536a4a61af053e1be4bf25292020-11-25T02:12:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5757810.1371/journal.pone.0057578Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.Xiaohua YeJinjian FuYi YangSidong ChenBACKGROUND: In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer. However, uncertainty remains on the exact dose-risk and duration-risk relationships. METHODS: We identified studies by searching several English and Chinese electronic databases and reviewing relevant articles. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Subgroup analyses were conducted to explore possible heterogeneity among studies. Potential heterogeneity was calculated as Q statistic and I(2) value. Publication bias was evaluated using funnel plots and quantified by the Begg's and Egger's test. RESULTS: Twelve studies were included in this meta-analysis. An inverse association between aspirin use and colorectal cancer was observed in both the overall group (RR = 0.74, 95% CI 0.64-0.83 for aspirin dose; RR = 0.80, 95% CI 0.75-0.85 for frequency of aspirin use; RR = 0.75, 95% CI 0.68-0.81 for years of aspirin use) and subgroups stratified by sex and cancer site. The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment. CONCLUSION: Long-term (>5 years), low-dose (75-325 mg per day) and regular aspirin use (2-7 times per week) can effectively reduce the risk of colorectal cancer.http://europepmc.org/articles/PMC3581483?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiaohua Ye Jinjian Fu Yi Yang Sidong Chen |
spellingShingle |
Xiaohua Ye Jinjian Fu Yi Yang Sidong Chen Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS ONE |
author_facet |
Xiaohua Ye Jinjian Fu Yi Yang Sidong Chen |
author_sort |
Xiaohua Ye |
title |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
title_short |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
title_full |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
title_fullStr |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
title_full_unstemmed |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
title_sort |
dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
BACKGROUND: In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer. However, uncertainty remains on the exact dose-risk and duration-risk relationships. METHODS: We identified studies by searching several English and Chinese electronic databases and reviewing relevant articles. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Subgroup analyses were conducted to explore possible heterogeneity among studies. Potential heterogeneity was calculated as Q statistic and I(2) value. Publication bias was evaluated using funnel plots and quantified by the Begg's and Egger's test. RESULTS: Twelve studies were included in this meta-analysis. An inverse association between aspirin use and colorectal cancer was observed in both the overall group (RR = 0.74, 95% CI 0.64-0.83 for aspirin dose; RR = 0.80, 95% CI 0.75-0.85 for frequency of aspirin use; RR = 0.75, 95% CI 0.68-0.81 for years of aspirin use) and subgroups stratified by sex and cancer site. The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment. CONCLUSION: Long-term (>5 years), low-dose (75-325 mg per day) and regular aspirin use (2-7 times per week) can effectively reduce the risk of colorectal cancer. |
url |
http://europepmc.org/articles/PMC3581483?pdf=render |
work_keys_str_mv |
AT xiaohuaye doseriskanddurationriskrelationshipsbetweenaspirinandcolorectalcancerametaanalysisofpublishedcohortstudies AT jinjianfu doseriskanddurationriskrelationshipsbetweenaspirinandcolorectalcancerametaanalysisofpublishedcohortstudies AT yiyang doseriskanddurationriskrelationshipsbetweenaspirinandcolorectalcancerametaanalysisofpublishedcohortstudies AT sidongchen doseriskanddurationriskrelationshipsbetweenaspirinandcolorectalcancerametaanalysisofpublishedcohortstudies |
_version_ |
1724907011082027008 |